Abcam, ab321985, Anti-EDC4 antibody [EPR28929-24] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal EDC4 antibody. Carrier free. Suitable for ICC/IF, IHC-P, WB and reacts with Human, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28929-24,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse,
Applications:ICC/IF, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab321985 is the carrier-free version of
ab321984
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
EDC4 also known as Enhancer of decapping 4 plays an important role in RNA processing mechanisms. It weighs around 145 kDa. EDC4 is widely expressed in many tissues and cells providing integral support to cellular processes. This protein partners with other decapping proteins in cells to manage RNA turnover ensuring precise degradation of RNA molecules that are no longer needed. Its presence within human tissues suggests its broad involvement in regulating gene expression.
Biological function summary
EDC4 assists in the formation of the decapping complex. This complex facilitates the removal of the 5' cap from mRNAs an essential step in mRNA decay. This decapping activity influences mRNA stability and degradation allowing cells to modulate protein synthesis according to environmental changes. EDC4 interacts with other decapping components like DCP1 further stabilizing its function within the decapping complex and aiding cellular homeostasis.
Pathways
EDC4 plays a part in the mRNA surveillance pathway which ensures the fidelity of gene expression by eliminating faulty mRNA transcripts. Also it participates in the nonsense-mediated decay (NMD) pathway removing mRNA containing premature stop codons. It works alongside proteins such as UPF1 and UPF2 in these pathways to maintain mRNA quality and prevent production of truncated proteins that might disrupt cellular functions.
Alterations in EDC4 expression can relate to neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and cancer. In particular the misregulation of mRNA decay processes can contribute to these conditions. EDC4 interacts with proteins like TDP-43 in the context of ALS where disrupted RNA metabolism features prominently in disease pathology. Understanding these interactions offers insight into therapeutically targeting the molecular mechanisms at play in these disorders.